1. Home
  2. GLOB vs BCRX Comparison

GLOB vs BCRX Comparison

Compare GLOB & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globant S.A.

GLOB

Globant S.A.

N/A

Current Price

$43.13

Market Cap

2.2B

Sector

Technology

ML Signal

N/A

Logo BioCryst Pharmaceuticals Inc.

BCRX

BioCryst Pharmaceuticals Inc.

N/A

Current Price

$9.64

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GLOB
BCRX
Founded
2003
1986
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
GLOB
BCRX
Price
$43.13
$9.64
Analyst Decision
Buy
Strong Buy
Analyst Count
14
11
Target Price
$79.14
$20.82
AVG Volume (30 Days)
1.4M
5.7M
Earning Date
02-26-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
381.40
EPS
N/A
1.21
Revenue
N/A
$25,186,000.00
Revenue This Year
$3.06
N/A
Revenue Next Year
$5.30
$12.55
P/E Ratio
$22.55
$8.02
Revenue Growth
N/A
N/A
52 Week Low
$40.77
$6.00
52 Week High
$142.25
$11.31

Technical Indicators

Market Signals
Indicator
GLOB
BCRX
Relative Strength Index (RSI) 33.74 70.01
Support Level $40.77 $7.99
Resistance Level $71.47 N/A
Average True Range (ATR) 2.12 0.48
MACD 0.16 0.07
Stochastic Oscillator 11.01 68.43

Price Performance

Historical Comparison
GLOB
BCRX

About GLOB Globant S.A.

Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.

About BCRX BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Share on Social Networks: